

## Final programme

### TUESDAY 3 JULY

- 08:55 *Crombie and Kings Hall residents – bus to AECC*
- 09:30 Coffee, registration, poster hanging
- 10:25 **Opening and welcome**  
Chair: *Stephen Logan*  
*Senior Vice-Principal, University of Aberdeen*
- Professor C Duncan Rice*  
*Principal & Vice-Chancellor of the University of Aberdeen*
- Bone pain**  
Chairs: Steven Goldring (New York, USA) and Jonathan Reeve (Cambridge, UK)
- 10:30 IS1 Acid and bone  
*Tim Arnett (London, UK)*
- 11:00 IS2 The role of the endocannabinoid system in pain modulation  
*Ruth Ross (Aberdeen, UK)*
- 11:30 IS3 Cannabinoids and bone  
*Rob van t'Hof (Edinburgh, UK)*
- 12:00 **Oral communications 1**  
Chairs: Tim Arnett (London, UK) and Miep Helfrich (Aberdeen, UK)
- 12:00 OC1 The endocannabinoids 2-arachidonoyl glycerol and anandamide are produced by bone cells and stimulate bone resorption in vitro  
*SA Ridge\*, L Ford, GA Cameron, RA Ross, MJ Rogers*  
*Bone & Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen UK*
- 12:12 OC2 Hypoxia-Inducible Factor and human osteoclasts: evidence for a positive feedback loop regulating osteoclast function  
*HJ Knowles\*, NA Athanasou*  
*Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, UK*
- 12:24 OC3 Intrauterine programming of bone-deleterious effects of a low protein diet in late adulthood on the osteogenic environment  
*SA Lanham<sup>\*[1]</sup>, C Roberts<sup>[1]</sup>, MJ Perry<sup>[2]</sup>, C Cooper<sup>[1]</sup>, ROC Oreffo<sup>[1]</sup>*  
*<sup>[1]</sup>Bone and Joint Research Group, Developmental Origins of Health and Disease, University of Southampton, Southampton, UK; <sup>[2]</sup>Department of Anatomy, University of Bristol, UK*
- 12:36 OC4 Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo  
*PD Ottewell<sup>\*[1]</sup>, B Deux<sup>[2]</sup>, H Mönkkönen<sup>[1]</sup>, RE Coleman<sup>[1]</sup>, P Clezardin<sup>[2]</sup>, I Holen<sup>[1]</sup>*  
*<sup>[1]</sup>Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, UK; <sup>[2]</sup>INSERM Research Unit 403, Faculté de Médecine Laënnec, 69372 Lyon Cedex 08, France*
- 12:48 OC5 Evaluation of in vivo neovascularisation in allograft and poly D,L-Lactic Acid tissue engineered scaffolds using micro-computer tomography  
*BJRF Bolland, JM Kanczler\*, DG Dunlop, ROC Oreffo*  
*Bone & Joint Research Group, Developmental Origins of Health and Disease, University of Southampton, Southampton SO16 6YD, UK*
- 13:00 Lunch and posters (odd numbers attended 13:30-14:30)
- Vesicular trafficking and bone disease**  
Chairs: Matthew Gillespie (Melbourne, Australia) and Mike Rogers (Aberdeen, UK)
- 14:30 IS4 Vesicular trafficking in osteoclast biology  
*Fraser Coxon (Aberdeen, UK)*
- 15:00 IS5 Diseases caused by defects in vesicular trafficking and acidification  
*Uwe Kornak (Berlin, Germany)*
- 15:30 IS6 Chloride channels as a target for bone therapy  
*Morten Karsdal (Herlev, Denmark)*

- 16:00 Tea
- 16:30 **Oral communications 2**  
Chairs: Bronwen Evans (Cardiff, UK) and Uwe Kornak (Berlin, Germany)
- 16:30 OC6 RANKL mutations are responsible for the defective osteoclast formation seen in six patients with osteoclast-poor osteopetrosis  
*DI Scott<sup>\*[1]</sup>, FP Coxon<sup>[1]</sup>, C Sobacchi<sup>[2]</sup>, A Frattini<sup>[2]</sup>, A Pangrazio<sup>[2]</sup>, M Guerrini<sup>[2]</sup>, L Susani<sup>[2]</sup>, A Teti<sup>[3]</sup>, C Messina<sup>[4]</sup>, G Errigo<sup>[4]</sup>, M Abinun<sup>[5]</sup>, A Cant<sup>[5]</sup>, N J Bishop<sup>[6]</sup>, P Grabowski<sup>[6]</sup>, RGM Bredius<sup>[7]</sup>, GMS Mancini<sup>[8]</sup>, PM Vezzoni<sup>[2]</sup>, A Villa<sup>[2]</sup>, MJ Rogers<sup>[1]</sup>, M Helfrich<sup>[1]</sup>*  
*[1] Department of Medicine and Therapeutics, University of Aberdeen, UK; [2] Institute of Biomedical Technologies, National Research Council, Segrate, Italy; [3] Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy; [4] Oncoematologia Pediatrica, Dipartimento di Pediatria, University of Padoa, Padoa, Italy; [5] Children's BMT Unit Newcastle General Hospital and School of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; [6] Sheffield Children's Hospital and Academic Unit of Child Health, University of Sheffield, Sheffield, UK; [7] Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; [8] Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands*
- 16:42 OC7 Downstream signalling pathways of non-canonical (RANKL-independent) pathways of osteoclast formation induced by TNF superfamily members LIGHT and APRIL  
*F Jones<sup>\*[1]</sup>, H Knowles<sup>[1]</sup>, NA Athanasou<sup>[2]</sup>*  
*[1] Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Oxford, OX3 7LD, UK; [2] Department of Pathology, Nuffield Orthopaedic Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, OX3 7LD, UK*
- 16:54 OC8 Mice with a truncation mutation affecting sequestosome 1 exhibit several phenotypic features in common with Paget's disease of bone  
*JA Rojas<sup>\*[1]</sup>, A Daroszevska<sup>[1]</sup>, M Helfrich<sup>[2]</sup>, R Layfield<sup>[3]</sup>, R van't Hof<sup>[1]</sup>, SH Ralston<sup>[1]</sup>*  
*[1] University of Edinburgh, Edinburgh, UK; [2] University of Aberdeen, Aberdeen, UK; [3] Institute of Neuroscience, University of Nottingham, Nottingham, UK*
- 17:06 OC9 Targeting osteoclasts in rheumatoid arthritis via the alpha(v)beta(3) integrin  
*F Brunton<sup>\*[1]</sup>, L Lee<sup>[1]</sup>, A Nissim<sup>[2]</sup>, AE Grigoriadis<sup>[3]</sup>, C Pitzalis<sup>[1]</sup>*  
*[1] Dept Rheumatology, KCL Guy's Hospital, London, UK; [2] William Harvey Research Institute, QMUL, London, UK; [3] Dept Craniofacial Dev, KCL Guy's Hospital, London, UK*
- 17:18 OC10 Suppressor of cytokine signalling-2 (SOCS-2) expression in the growth plate: modulation by pro-inflammatory cytokines.  
*VE MacRae<sup>\*[1]</sup>, S Pells<sup>[1]</sup>, SF Ahmed<sup>[2]</sup>, C Farquharson<sup>[1]</sup>*  
*[1] Roslin Institute, Midlothian, UK; [2] Royal Hospital for Sick Children, Glasgow, UK*
- 17:30 Close
- 17:40 *Crombie and Kings Hall residents – bus from AECC to Halls*
- 18:30 *Crombie and Kings Hall residents – bus to Town and County Hall*
- 19:00 **Civic Reception** at the Town and County Hall

## WEDNESDAY 4 JULY

07:55 Crombie and Kings Hall residents – bus to AECC

### Signalling pathways and bone formation

Chairs: Brendon Noble (Edinburgh, UK) and Jon Tobias (Bristol, UK)

- 08:30 IS7 Control of bone remodeling homeostasis via the autonomous nervous system  
*Florent Elefteriou (Nashville, USA)*
- 09:00 IS8 Discovery of the fibrodysplasia ossificans progressiva (FOP) gene  
*Matthew Brown (Brisbane, Australia)*
- 09:30 IS9 Role of sclerostin in BMP and Wnt signalling: implications for bone formation  
*Wendy Balemans (Antwerp, Belgium)*

### 10:00 Oral communications 3

Chairs: Matthew Brown (Brisbane, Australia) and Claire Clarkin (London, UK)

- 10:00 OC11 An atypical mutation in the activin A receptor, type 1 gene (ACVR1) in a severely affected fibrodysplasia ossificans progressiva patient  
*KA Petrie\*, JJ Pointon, R Smith, RGG Russell, PW Wordsworth, JT Triffitt*  
*Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX120JH, UK*
- 10:12 OC12 Osteocyte sclerostin expression: regulator of BMU balance in osteoarthritis and osteoporosis?  
*N Loveridge<sup>[1]</sup>, J Power<sup>[1]</sup>, A Caballero-Alias<sup>[1]</sup>, R van Bezooijen<sup>[2]</sup>, S Papapoulos<sup>[2]</sup>, C Lowik<sup>[2]</sup>, KE Poole<sup>[1]</sup>, J Reeve<sup>[1]\*</sup>*  
*<sup>[1]</sup>University of Cambridge, Cambridge, UK; <sup>[2]</sup>University of Leiden, Leiden, The Netherlands*
- 10:24 OC13 Interrogating the mechanisms controlling osteocytogenesis  
*M Prideaux\*<sup>[1,2]</sup>, A Pitsillides<sup>[2]</sup>, L Bonewald<sup>[3]</sup>, N Loveridge<sup>[4]</sup>, C Farquharson<sup>[1]</sup>*  
*<sup>[1]</sup>Roslin Institute, Edinburgh, UK; <sup>[2]</sup>Royal Veterinary College, London, UK; <sup>[3]</sup>School of Dentistry, University of Missouri-Kansas City, USA; <sup>[4]</sup>University of Cambridge, Cambridge, UK*
- 10:36 OC14 Spondyloepiphyseal dysplasia tarda (SED)-associated Sedlin mutations disrupt interactions with c-myc promoter-binding protein 1 (MBP-1), pituitary homeobox 1 (Pitx1) and steroidogenic factor 1 (SF1)  
*MA Nesbit\*<sup>[1]</sup>, J Jeyabalan<sup>[1]</sup>, HA Ingraham<sup>[2]</sup>, RV Thakker<sup>[1]</sup>*  
*<sup>[1]</sup>Academic Endocrine Unit, Nuffield Department of Clinical Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK; <sup>[2]</sup>Department of Physiology, University of California, San Francisco, California, USA*
- 10:48 OC15 Wnt signalling upregulates osteoblast differentiation in zebrafish: a novel model for studies in osteoblastogenesis  
*PM Elks\*, N Li, HH Roehl, PI Croucher*  
*University of Sheffield, Sheffield, UK*

11:00 Coffee

### Bone loss and inflammatory arthritis

Chairs: Cyrus Cooper (Southampton, UK) and Richard Keen (London, UK)

- 11:30 IS10 Determinants of bone destruction in rheumatoid arthritis  
*Steven Goldring (New York, USA)*
- 12:00 IS11 Role of cytokines and bone: use of *in vitro* models  
*Matt Gillespie (Melbourne, Australia)*
- 12:30 IS12 Modulation of T cell function in rheumatoid arthritis  
*Berent Prakken (Utrecht, Netherlands)*

13:00 Lunch and posters (even numbers attended 13:30-14:30)

### 14:30 Oral communications 4

Chairs: Kay Colston (London, UK) and Florent Elefteriou (Nashville, USA)

- 14:30 OC16 The local and systemic effects of glucocorticoid generation in synovium  
*RS Hardy<sup>[1]\*</sup>, EH Rabbitt<sup>[1]</sup>, K Raza<sup>[2]</sup>, CD Buckley<sup>[2]</sup>, PM Stewart<sup>[1]</sup>, MC Cooper<sup>[1]</sup>*  
*<sup>[1]</sup>Division of Medical Sciences, University of Birmingham, West Midlands, UK; <sup>[2]</sup>Division of Rheumatology, University of Birmingham, West Midlands, UK*
- 14:42 OC17 Auto-induction of IL-1beta and loss of promoter methylation: a possible explanation of the unremitting progression of osteoarthritis?  
*MB Gibson<sup>[1]</sup>, K Hashimoto<sup>[1,2]</sup>, HI Roach\*<sup>[1]</sup>*

- [1]Bone & Joint Research Group, University of Southampton, UK; [2]Tohoku University, Sendai, Japan*
- 14:54 OC18 Identification of lipocalin 2, a novel glucocorticoid responsive gene in growth plate chondrocytes  
*HC Owen\*<sup>[1][2]</sup>, SF Ahmed<sup>[2]</sup>, C Farquharson<sup>[1]</sup>*  
*[1]Bone Biology Group, Roslin Institute, Edinburgh, UK; [2]Bone & Endocrine Research Group, Royal Hospital for Sick Children, Glasgow, UK*
- 15:06 OC19 Childhood physical activity is associated with bone mass at 4 years  
*N Harvey\*<sup>[1]</sup>, K Westgate<sup>[2]</sup>, S Brage<sup>[2]</sup>, L Greenaway<sup>[1]</sup>, J Poole<sup>[1]</sup>, E Dennison<sup>[1]</sup>, H Inskip<sup>[1]</sup>, K Godfrey<sup>[1]</sup>, N Wareham<sup>[2]</sup>, U Ekelund<sup>[2]</sup>, C Cooper<sup>[1]</sup>*  
*[1]MRC Epidemiology Resource Centre, Southampton, UK; [2] MRC Epidemiology Unit, Cambridge, UK*
- 15:18 OC20 Body Mass Index is more predictive of the osteogenic potential of bone marrow stromal cells than age in males  
*RM McCann\*<sup>[1]</sup>, GR Jordan<sup>[1]</sup>, D Beverland<sup>[2]</sup>, SA Clarke<sup>[1]</sup>*  
*[1]Trauma Research Group, Queen's University, Belfast, UK; [2]Department of Orthopaedic Surgery, Musgrave Park Hospital, Belfast, UK*
- 15:30 OC21 Genetic manipulation of human mesenchymal progenitors to promote chondrogenesis within polysaccharide templates  
*JC Babister\*, RS Tare, DW Green, S Inglis, ROC Oreffo*  
*Bone & Joint Research Group, Developmental Origins of Health and Disease, University of Southampton, Southampton, SO16 6YD, UK*
- 15:42 OC22 A soluble activin type II receptor prevents myeloma bone disease  
*AD Chantry\*<sup>[1]</sup>, D Heath<sup>[1]</sup>, L Coulton<sup>[1]</sup>, O Gallagher<sup>[1]</sup>, H Evans<sup>[1]</sup>, J Seehra<sup>[2]</sup>, K Vanderkerken<sup>[3]</sup>, PI Croucher<sup>[1]</sup>*  
*[1]Section of Musculoskeletal Science, University of Sheffield Medical School, Sheffield, UK; [2]Acceleron Pharma, Cambridge, MA, USA; [3]Department Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium*
- 16:00 Tea
- 16:30 **Oral posters**
- 16:30 OP1 Segmental bone regeneration using vascular endothelial growth factor encapsulated poly D,L-Lactic Acid scaffolds and human bone marrow stromal cells  
*JM Kanczler\*<sup>[1]</sup>, J Barry<sup>[2]</sup>, P Ginty<sup>[2]</sup>, SM Howdle<sup>[2]</sup>, KM Shakesheff<sup>[2]</sup>, ROC Oreffo<sup>[1]</sup>*  
*[1] Bone & Joint Group, University of Southampton, UK; [2]School of Pharmacy & Chemistry, University of Nottingham, UK*
- 16:35 OP2 CP55940, a non-selective CB1/CB2 agonist, stimulates bone resorption by human osteoclasts in vitro  
*L Whyte\*, S Ridge, R Ross, MJ Rogers*  
*Aberdeen OBRP Centre, Bone & Musculoskeletal Research Programme, University of Aberdeen, UK*
- 16:40 OP3 Dietary flavonoid intake is associated with bone mineral density in early postmenopausal Scottish women  
*AC Hardcastle\*<sup>[1,2]</sup>, JAM Kyle<sup>[2]</sup>, G Duthie<sup>[3]</sup>, G Mc Neill<sup>[2]</sup>, DM Reid<sup>[1,2]</sup>, HM MacDonald<sup>[1,2]</sup>*  
*[1]Osteoporosis Research Unit, Health Sciences Building, University of Aberdeen, UK; [2]College of Medicine, University of Aberdeen, UK; [3]Rowett Research Institute, Aberdeen, UK*
- 16:45 OP4 Femoral neck microarchitecture: differences between cases of hip fracture and controls  
*N Loveridge\*<sup>[1]</sup>, J Power<sup>[1]</sup>, H Kroger<sup>[2]</sup>, M Parker<sup>[3]</sup>, J Reeve<sup>[1]</sup>*  
*[1]Bone Research Group, Cambridge, UK; [2]University Hospital, Kuopio, Finland; [3]District Hospital, Peterborough, UK*
- 16:50 OP5 Chondrocytes in osteoarthritis de-differentiate to a progenitor-like intermediate before re-differentiating to a complex and mixed phenotype  
*MA Da Silva, HI Roach\**  
*Bone & Joint Research Group, University of Southampton, General Hospital, Southampton, UK*
- 16:55 OP6 *Abstract Withdrawn*
- 17:00 OP7 Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis  
*RM Locklin\*<sup>[1]</sup>, RGG Russell<sup>[1]</sup>, PI Croucher<sup>[2]</sup>, CM Edwards<sup>[3]</sup>*  
*[1]Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, UK; [2]Division of Clinical Sciences, University of Sheffield Medical School, Sheffield, UK; [3]Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA*
- 17:05 OP8 The expression and regulation of Bim in osteoblasts undergoing growth factor withdrawal  
*M Liang\*, RGG Russell, PA Hulley*  
*Botnar Research Centre, Nuffield Dept of Orthopaedic Surgery, University of Oxford, UK*

- 17:10 OP9 Novel control of GAG synthesis and chondrogenesis through selective regulation of UDPGD-mediated monosaccharide supply  
*CE Clarkin\**, *S Allen*, *BT Wheeler*, *CPD Wheeler-Jones*, *AA Pitsillides*  
*The Royal Veterinary College, London, UK*
- 17:15 OP10 The effect of tensile forces on the differentiation of mesenchymal stem cells  
*SB Mirza\**, *M Greenwood*, *G Blunn*  
*Institute of Orthopaedics, University College London, UK*
- 17:20 OP11 Genetic mutations in the RAS/RAF/MAPKinase pathway results in cherubism  
*BD Idowu*<sup>[1]</sup>, *J Mangion*<sup>[2]</sup>, *RE Gale*<sup>[3]</sup>, *AM Flanagan*<sup>[4]</sup>  
<sup>[1]</sup>*Institute of Orthopaedics, UCL, London, UK;* <sup>[2]</sup>*MRC Clinical Sciences Centre, Imperial College London, UK;* <sup>[3]</sup>*Department of Haematology, UCL, London, UK;* <sup>[4]</sup>*Institute of Orthopaedics, UCL, London, UK*

17.30

**Keynote Lecture**

Chair: C Duncan Rice

*Principal & Vice-Chancellor of the University of Aberdeen*

Ethical considerations and medical research: past, present and future

*Neva Haites (Aberdeen, UK)*

*Head of the College of Life Sciences and Medicine*

18:10

*Crombie and Kings Hall residents – bus from AECC to Halls*

19:20

*Crombie and Kings Hall residents – bus to Beach Ballroom*

19:45

**Annual Dinner and Ceilidh** in the Beach Ballroom

## THURSDAY 5 JULY

08:25 Crombie and Kings Hall residents – bus to AECC

### Contemporary issues in therapeutics of bone

Chairs: Richard Eastell (Sheffield, UK) and Nick Harvey (Southampton, UK)

- 09:00 IS13 Role of bisphosphonates in cancer management  
*Robert Coleman (Sheffield, UK)*
- 09:30 IS14 Bisphosphonates in the management of Paget's disease  
*Stuart Ralston (Edinburgh, UK)*
- 10:00 IS15 Therapeutic options after bisphosphonates  
*Graham Russell (Oxford, UK)*

10:30 Coffee

### Oral communications 5

Chairs: Mark Cooper (Birmingham, UK) and Graham Russell (Oxford, UK)

- 11:00 OC23 Height loss predicts fractures in middle aged and older men and women: the EPIC-Norfolk prospective population study  
*A Moayyeri<sup>\*[1]</sup>, RN Luben<sup>[1]</sup>, S Bingham<sup>[2]</sup>, A Welch<sup>[1]</sup>, NJ Wareham<sup>[3]</sup>, KT Khaw<sup>[1]</sup>*  
*<sup>[1]</sup>Department of Public Health and Primary Care, Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK; <sup>[2]</sup>MRC Dunn Human Nutrition Unit, Cambridge, UK; <sup>[3]</sup>MRC Epidemiology Unit, Cambridge, UK*
- 11:12 OC24 Autologous conditioned serum (ACS) compared to hyaluronan and saline-injections for the treatment of knee osteoarthritis  
*C Moser<sup>\*[1,2]</sup>, AWA Baltzer<sup>[2]</sup>, R Krauspe<sup>[1]</sup>, P Wehling<sup>[2]</sup>*  
*<sup>[1]</sup>Department of Orthopaedics, Heinrich Heine University Hospital Duesseldorf, Germany; <sup>[2]</sup>Centre for Molecular Orthopaedics, Königsallee 53-55, Duesseldorf, Germany*
- 11:24 OC25 An international multicenter randomized comparison of balloon kyphoplasty and nonsurgical care in patients with acute vertebral body compression fractures  
*D Wardlaw<sup>\*[1]</sup>, S Boonen<sup>[2]</sup>, L Bastian<sup>[3]</sup>, J Van Meirhaeghe<sup>[4]</sup>, AZ St Jan<sup>[4]</sup>*  
*<sup>[1]</sup>Department of Orthopaedics, Woodend Hospital, Eday Road, Aberdeen, UK; <sup>[2]</sup>UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium; <sup>[3]</sup>Medizinische Hochschule Hannover, Unfallchirurgie, Carl Neuberg Str. 1, 30625 Hannover, Germany; <sup>[4]</sup>Dept Orthopaedics, Ruddershove 10, 8000 Brugge, Belgium*
- 11:36 OC26 Muscle function and the effects of hypovitaminosis D in post-menarchal females  
*KA Ward<sup>\*[1]</sup>, G Das<sup>[2]</sup>, JL Berry<sup>[1]</sup>, SA Roberts<sup>[1]</sup>, R Rawer<sup>[3]</sup>, JE Adams<sup>[1]</sup>, MZ Mughal<sup>[4]</sup>*  
*<sup>[1]</sup>University of Manchester, Manchester, UK; <sup>[2]</sup>Central Manchester Primary Care Trust, Manchester, UK; <sup>[3]</sup>Novotec Medical, Manchester, UK; <sup>[4]</sup>Central Manchester & Manchester Childrens University Hospitals NHS Trust, Manchester, UK*
- 11:48 OC27 Effect of the dual-specific Src/Abl kinase inhibitor AZD0530 on bone turnover in patients with advanced solid malignancies  
*RA Hannon<sup>\*[1]</sup>, G Clack<sup>[2]</sup>, RB Iacona<sup>[3]</sup>, P Baker<sup>[2]</sup>, M Rimmer<sup>[2]</sup>, F Gossie<sup>[1]</sup>, IC Smith<sup>[2]</sup>, A Robinson<sup>[2]</sup>, R Eastell<sup>[1]</sup>*  
*<sup>[1]</sup>Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK; <sup>[2]</sup>AstraZeneca, Alderley Park, Macclesfield, UK; <sup>[3]</sup>AstraZeneca, Wilmington, Delaware, USA*

### Clinical cases

Chairs: Piet Geusens (Maastricht, Netherlands) and Stuart Ralston (Edinburgh, UK)

- 12:00 CC1 Severe high turnover osteoporosis of unknown cause in a young man with autoimmune hypothyroidism ; a novel syndrome?  
*PL Riches<sup>\*</sup>, E McRorie, SH Ralston*  
*Centre for Rheumatic Diseases, Western General Hospital, Edinburgh, UK*
- 12:15 CC2 Residual (Ghost) sockets in intravenous bisphosphonate use - evidence of poor healing and slow bone turnover  
*K Shetty<sup>\*</sup>, J Buoquot*  
*University of Texas Health Science Center, Houston, US*
- 12:30 CC3 Bone pain from chronic sclerosing osteomyelitis successfully treated with risedronate  
*SE Green<sup>\*[1]</sup>, RW Keen<sup>[2]</sup>*  
*<sup>[1]</sup>Rheumatology Department, Ysbyty Gwynedd, Bangor, Gwynedd, LL57 2PW, UK; <sup>[2]</sup>Royal National Orthopaedic Hospital, Stanmore, Middlesex, HA7 4LP, UK*
- 12:45 CC4 Osteoclast activity in childhood acute lymphoblastic leukaemia (ALL) during the first year of treatment  
*RM Cox<sup>[1]</sup>, JW Gregory<sup>[1]</sup>, JH Davies<sup>[2]</sup>, MEM Jenney<sup>[3]</sup>, WD Fraser<sup>[4]</sup>, BAJ Evans<sup>\*[1]</sup>*

<sup>[1]</sup>Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK;<sup>[2]</sup>Southampton University Hospital NHS Trust, Southampton, UK;<sup>[3]</sup>Paediatric Oncology, University Hospital of Wales, Cardiff, UK;<sup>[4]</sup>Clinical Chemistry, University of Liverpool, Liverpool, UK

13:00 Lunch

13:30 BRS AGM

**Bone and rheumatoid arthritis**

Chairs: David Reid (Aberdeen, UK) and *tbc*

*Generously supported by an unrestricted educational grant from Amgen*

14:00 Assessment of bone loss in the prediction of long-term disease activity in rheumatoid arthritis  
*Paul Emery (Leeds, UK)*

14:30 Role of RANK/RANKL pathway in the bone loss of rheumatoid arthritis  
*Kurt Redlich (Vienna, Austria)*

15:00 Potential for RANKL inhibition in the management of rheumatoid arthritis  
*Piet Geusens (Maastricht, Netherlands)*

15:30 Close

15:40 *Buses from AECC to Aberdeen Airport*

## POSTERS

- P12 Nitrogen-containing bisphosphonates and prediction of their clinical potencies: dissociation of target enzyme- and hydroxyapatite-binding affinities  
*Z Xia<sup>[1]\*</sup>, J Dunford<sup>[1]</sup>, MA Lawson<sup>[1]</sup>, JT Triffitt<sup>[1]</sup>, K Kavanagh<sup>[1]</sup>, U Oppermann<sup>[1]</sup>, BL Barnett<sup>[2]</sup>, FH Ebetino<sup>[2]</sup>, RGG Russell<sup>[1]</sup>*  
<sup>[1]</sup>The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Orthopaedic Centre, Oxford, OX3 7LD, UK; <sup>[2]</sup>New Drug Development, Procter and Gamble Pharm, Cincinnati OH, USA; <sup>[3]</sup>Chemistry Department, University of Southern California, Los Angeles, CA, USA
- P13 Mcl-1 is an important pro-survival factor in osteoclasts  
*K McConachie, D Tosh, MJ Rogers\**  
 University of Aberdeen, Aberdeen, UK.
- P14 Adenosine stimulates mineralisation of rat mesenchymal stem cells in vitro  
*B Gharibi<sup>\*[1,2]</sup>, C Elford<sup>[1]</sup>, J Ham<sup>[2]</sup>, BAJ Evans<sup>[1]</sup>*  
<sup>[1]</sup>Department of Child Health, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; <sup>[2]</sup>Centre for Endocrine and Diabetes Research, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
- P15 Compartmentalisation of GFP-tagged ER-alpha and ER-GR constructs in bone (ROS) and breast (MCF-7) cells  
*BS Maru<sup>\*[1]</sup>, MR Norman<sup>[1]</sup>, JH Tobias<sup>[2]</sup>, CA McArdle<sup>[1]</sup>*  
<sup>[1]</sup>Dorothy Hodgkin Building, University of Bristol, Whitson Street, Bristol, UK; <sup>[2]</sup>Rheumatology Unit, Bristol Royal Infirmary, Marlborough Street, Bristol, UK
- P16 Osteopenia in 129Sv/Ev Sparctm1cam mice: bone phenotypic characterization and gene expression changes  
*FC Mansergh<sup>[1]</sup>, T Wells<sup>[1]</sup>, C Elford<sup>[2]</sup>, SL Evans<sup>[3]</sup>, MJ Perry<sup>[4]</sup>, MJ Evans<sup>[1]</sup>, BAJ Evans<sup>\*[2]</sup>*  
<sup>[1]</sup>School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, UK; <sup>[2]</sup>Department of Child Health, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; <sup>[3]</sup>School of Engineering, Cardiff University, The Parade, Cardiff CF24 3AA, UK; <sup>[4]</sup>Department of Anatomy, University of Bristol, Bristol BS2 8EJ, UK
- P17 SB431542, a TGF-beta type 1 receptor inhibitor, promotes C2C12 myotube hypertrophy  
*K Watt\*, A Ratkevicius, H Wackerhage*  
 Bone Research Group, Institute of Medical Sciences, University of Aberdeen, UK
- P18 Polymorphic variation in the FPP synthase (FPPS) gene and effects on bisphosphonate inhibition  
*C Roemelt<sup>\*[1]</sup>, F McGuigan<sup>[2]</sup>, J Dunford<sup>[3]</sup>, O Albaghal<sup>[4]</sup>, MJ Rogers<sup>[1]</sup>*  
<sup>[1]</sup>Bone & Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK; <sup>[2]</sup>Clinical & Molecular Osteoporosis Research Unit, Malmö University Hospital Malmö, Sweden SE-205 02; <sup>[3]</sup>Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, UK; <sup>[4]</sup>Rheumatology Section, Molecular Medicine Centre, University of Edinburgh School of Molecular and Clinical Medicine, Western General Hospital, Edinburgh, EH4 2XU, UK
- P19 Human osteoclast formation and activity on bone substitute biomaterials  
*V Perrotti<sup>[1,2]</sup>, BM Nicholls<sup>\*[1]</sup>, MA Horton<sup>[1]</sup>, A Piattelli<sup>[2]</sup>*  
<sup>[1]</sup>University College London, Bone and Mineral Centre, London, UK; <sup>[2]</sup>University of Chieti-Pescara, Dental School, Chieti, Italy
- P20 Zoledronate potently inhibits the growth, survival and activity of normal rat osteoblasts  
*IR Orriss\*, JC Utting, ML Key, A Brandao-Burch, KW Colston, TR Arnett*  
 Department of Anatomy and Developmental Biology, University College London, London, UK
- P21 Differential vascular endothelial growth factor receptor expression during osteogenesis  
*G Kirmizidis<sup>\*[1]</sup>, JH Lakey<sup>[2]</sup>, MA Birch<sup>[1]</sup>*  
<sup>[1]</sup>Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, UK; <sup>[2]</sup>Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, UK
- P22 Bone formation and fibrocartilage regeneration at bone tendon junction with allogeneic cultured chondrocyte pellet interposition  
*MWN Wong<sup>\*[1]</sup>, KO Tai<sup>[1]</sup>, KM Lee<sup>[2]</sup>, L Qin<sup>[1]</sup>, KS Leung<sup>[1]</sup>*  
<sup>[1]</sup>Department of Orthopaedics and Traumatology; <sup>[2]</sup>Lee Hysan Research Laboratory, The Chinese University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region of China
- P23 Bcl-2-associated athanogene-1: A transcriptional regulator mediating chondrocyte survival and differentiation during endochondral ossification  
*RS Tare<sup>\*[1]</sup>, PA Townsend<sup>[2]</sup>, GK Packham<sup>[3]</sup>, S Inglis<sup>[1]</sup>, ROC Oreffo<sup>[1]</sup>*  
<sup>[1]</sup>Bone & Joint Research Group; <sup>[2]</sup>Human Genetics; <sup>[3]</sup>Cancer Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
- P24 Nitric oxide regulates expression of Class 3 semaphorins in mouse osteoblasts  
*A Hughes<sup>\*[1]</sup>, M Helfrich<sup>[1]</sup>, SH Ralston<sup>[2]</sup>, MJ Rogers<sup>[1]</sup>*  
<sup>[1]</sup>Bone & Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK; <sup>[2]</sup>Molecular Medicine Centre, Western General Hospital, Crewe Road West, Edinburgh, EH4 2XU, UK
- P25 Differential effects of alpha-halogenation on the potency of bisphosphonates and phosphonocarboxylates for inhibition of their target enzymes  
*CA Stewart<sup>\*[1]</sup>, JE Dunford<sup>[2]</sup>, Z Xia<sup>[2]</sup>, R Baron<sup>[3]</sup>, MS Marma<sup>[4]</sup>, BA Kashemirov<sup>[4]</sup>, CE McKenna<sup>[4]</sup>, FH Ebetino<sup>[5]</sup>, FP Coxon<sup>[1]</sup>*

<sup>[1]</sup>Bone Research Group, Institute of Medical Sciences, University of Aberdeen, AB25 2ZD, UK;<sup>[2]</sup>Botnar Research Centre, University of Oxford, UK;<sup>[3]</sup>Imperial College, London, UK;<sup>[4]</sup>Dept. of Chemistry, University of Southern California, Los Angeles, CA, USA;<sup>[5]</sup>Procter & Gamble Pharmaceuticals, Cincinnati OH, USA

- P26 Un-coupling of bone turnover markers following glucocorticoid therapy for exacerbations of inflammatory bowel disease  
MH Kriel<sup>\*[1]</sup>, CS Probert<sup>[1]</sup>, WD Fraser<sup>[2]</sup>, JH Tobias<sup>[1]</sup>  
<sup>[1]</sup>University of Bristol, Bristol, UK;<sup>[2]</sup>University of Liverpool, Liverpool, UK
- P27 Bone prophylaxis in steroid therapy: Are we doing enough?  
T Dugal<sup>[1]</sup>, B Hameed<sup>\*[1]</sup>, S Jawed<sup>[2]</sup>  
<sup>[1]</sup>St Georges Hospital Tooting, London;<sup>[2]</sup>St Thomas's Hospital London;<sup>[3]</sup>Kingston Hospital London
- P28 The pharmacology and putative function of BK channels in human osteoblast-like cells  
B Li<sup>\*[1]</sup>, BAJ Evans<sup>[2]</sup>, KT Wann<sup>[1]</sup>  
<sup>[1]</sup>Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Ave, Cardiff CF10 3XF, UK;<sup>[2]</sup>Department of Child Health, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
- P29 Detection of acoustic emissions to assess press-fit stability and fracture propagation during the insertion of a simulated implant for cementless hip replacement.  
BP Tweedie<sup>\*</sup>, AY Muir, HA Simpson  
Edinburgh Orthopaedic Engineering Centre, Chancellor's Building, University of Edinburgh, UK
- P30 Gas6 and Axl receptor tyrosine kinase are expressed by growth plate chondrocytes and osteoblasts  
L Ronaldson<sup>\*[1,2]</sup>, A Canfield<sup>[2]</sup>, C Farquharson<sup>[1]</sup>  
<sup>[1]</sup>Gene Function and Development, Roslin Institute, Roslin, Midlothian, UK;<sup>[2]</sup>Cardiovascular and Endocrine Sciences, School of Medicine, University of Manchester, Manchester, UK
- P31 The use of skeletal age to verify chronological age in youth football players  
M Johnson<sup>\*[1]</sup>, P Doherty<sup>[2]</sup>, AJ Freemont<sup>[3]</sup>  
<sup>[1]</sup>Manchester United Football Club, Manchester, UK;<sup>[2]</sup>York St John University, York, UK;<sup>[3]</sup>Manchester University, Manchester, UK
- P32 Extent of vitamin D insufficiency in young British women: influence on bone health  
JL Berry<sup>[1]\*</sup>, DP Pattison<sup>[2]</sup>, AD Woolf<sup>[2]</sup>, SA Lanham-New<sup>[3]</sup>  
<sup>[1]</sup>University of Manchester, UK;<sup>[2]</sup>University of Plymouth, UK;<sup>[3]</sup>University of Surrey, UK
- P33 Does hip arthritis limit the life expectancy in the elderly: A comparative study of operated and non-operated groups of patients suffering from hip osteoarthritis  
SVM Karuppiah, A Dhaliwal, WM Ledingham  
Department of Orthopaedics, Grampian University Hospitals Trust, Woodend Hospital, Eday Road Aberdeen AB25 2ZN, Scotland, UK
- P34 The subcellular localisation of FEO-RANK is altered when co-expressed with wildtype RANK protein in vitro  
JC Crockett<sup>\*</sup>, M Helfrich, MJ Rogers  
Bone Research Group, Institute of Medical Sciences, University of Aberdeen, UK
- P35 Altered lipid content in osteoarthritic femurs, assessed using MRI  
T Ahearn, JS Gregory<sup>\*</sup>, TW Redpath, RM Aspden, JD Hutchison, S Semple, D Younie, D Knight, FJ Gilbert  
University of Aberdeen, UK
- P36 Changes in structural properties lead to reduced bone strength in Gunmetal mice  
SR Goodyear<sup>\*[1,2]</sup>, A Taylor<sup>[1]</sup>, FP Coxon<sup>[1]</sup>, IR Gibson<sup>[1,2]</sup>, JMS Skakle<sup>[2]</sup>, RPK Wells<sup>[2]</sup>, RM Aspden<sup>[1]</sup>  
<sup>[1]</sup>Department of Orthopaedics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK;<sup>[2]</sup>Department of Chemistry, University of Aberdeen, Meston Walk, Aberdeen, AB24 3UE, UK
- P37 Inter and Intra-observer repeatability of Kellgren-Lawrence grading for osteoarthritis using DXA images  
CD Campbell<sup>\*</sup>, JS Gregory, K Yoshida, N Basu, A Stewart, DM Reid, RM Aspden  
Bone Research Programme, University of Aberdeen, UK
- P38 Assessment of osteoporosis and osteoarthritis using active shape and active appearance models with DXA scans  
JS Gregory<sup>\*</sup>, RJ Barr, A Stewart, DM Reid, RM Aspden  
Bone Research Programme, University of Aberdeen, UK
- P39 Atypical pharmacology of P2X7 receptors in human osteoblasts  
SM Al-qallaf<sup>\*[1,2]</sup>, EJ Kidd<sup>[1]</sup>, BAJ Evans<sup>[2]</sup>  
<sup>[1]</sup>Welsh School of Pharmacy, Cardiff University, Cardiff, UK;<sup>[2]</sup>Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK
- P40 eNOS knock out mice show reduced translocation of beta-Catenin to the nucleus when stimulated with pulsatile or oscillating fluid flow  
C Huesa<sup>\*[1,2]</sup>, A Hughes<sup>[1]</sup>, RM Aspden<sup>[2]</sup>, MH Helfrich<sup>[1]</sup>  
<sup>[1]</sup>Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK;<sup>[2]</sup>Department of Orthopaedics, University of Aberdeen, Aberdeen, UK
- P41 The role of p21CIP1/WAF1 in glucocorticoid induced growth retardation  
HC Owen<sup>\*[1][2]</sup>, SF Ahmed<sup>[2]</sup>, C Farquharson<sup>[1]</sup>  
<sup>[1]</sup>Bone Biology Group, Roslin Institute, Edinburgh, UK;<sup>[2]</sup>Bone & Endocrine Research Group, Royal Hospital for Sick Children, Glasgow, UK

- P42 Variation in Wnt-7a is unlikely to be a cause of familial Congenital Talipes Equinovarus  
*G Liu<sup>[1]</sup>, J Inglis<sup>[1]</sup>, A Cardy<sup>[2]</sup>, D Shaw<sup>[1]</sup>, S Sahota<sup>[1]</sup>, L Sharp<sup>[3]</sup>, Z Miedzybrodzka<sup>\*[1]</sup>*  
<sup>[1]</sup> Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK;<sup>[2]</sup> Department of Public Health, University of Aberdeen, Aberdeen, Scotland, UK;<sup>[3]</sup> National Cancer Registry Ireland, Cork, Ireland
- P43 Effects of ageing on cortical and trabecular bone in radius and tibia: a high-resolution pQCT study  
*S Kaptoge<sup>\*[1]</sup>, N Dalzell<sup>[1]</sup>, N Morris<sup>[2]</sup>, B Koller<sup>[3]</sup>, P Ruegsegger<sup>[3]</sup>, A Berthier<sup>[4]</sup>, L Braak<sup>[4]</sup>, J Reeve<sup>[1]</sup>*  
<sup>[1]</sup> Department of Medicine, University of Cambridge, Cambridge, UK;<sup>[2]</sup> Hethersett Surgery, Norfolk, UK;<sup>[3]</sup> Scanco, Zurich, Switzerland;<sup>[4]</sup> MEDES, Toulouse, France
- P44 Bone marrow stromal cells and biomimetic collagen-hydroxyapatite scaffolds for skeletal tissue engineering  
*JJ Dawson<sup>\*[1]</sup>, DA Wahl<sup>[2]</sup>, JT Czernuszka<sup>[2]</sup>, ROC Oreffo<sup>[1]</sup>*  
<sup>[1]</sup> University of Southampton, Southampton, UK;<sup>[2]</sup> Oxford University, Oxford, UK
- P45 A nouvelle method of application of tensile forces to mesenchymal stem cells  
*M Greenwood, SB Mirza\*, G Blunn*  
 Institute of Orthopaedics, University College London, London, UK
- P46 Regulation of osteogenic marker gene expression by growth hormone in osteoblastic cells derived from human alveolar bone is donor age-dependent  
*MM Beloti\*, GE Crippa, CR Cardoso, JS Silva, AL Ros*  
 University of Sao Paulo, Ribeirao Preto, SP, Brazil
- P47 High Density Polyethylene as a substitute for bones in biomechanical studies  
*SV Karupiah<sup>\*[1]</sup>, AJ Johnstone<sup>[1]</sup>*  
<sup>[1]</sup> Robert Gordon University, Department of Engineering, Aberdeen, Scotland, UK
- P48 Cortical and trabecular bone from mice compared by Raman spectroscopy  
*SR Goodyear<sup>\*[1,2]</sup>, IR Gibson<sup>[1,2]</sup>, JMS Skakle<sup>[2]</sup>, RPK Wells<sup>[2]</sup>, RM Aspden<sup>[1]</sup>*  
<sup>[1]</sup> Department of Orthopaedics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK;<sup>[2]</sup> Department of Chemistry, University of Aberdeen, Meston Walk, Aberdeen, AB24 3UE, UK
- P49 The mechanical, material and chemical properties of cortical bone from nNOS null mice  
*SR Goodyear<sup>\*[1,3]</sup>, RJ van't Hof<sup>[2]</sup>, IR Gibson<sup>[1,3]</sup>, JMS Skakle<sup>[3]</sup>, RPK Wells<sup>[3]</sup>, RM Aspden<sup>[1]</sup>*  
<sup>[1]</sup> Department of Orthopaedics, Institute of Medical Sciences, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK;<sup>[2]</sup> Rheumatology Section, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, UK;<sup>[3]</sup> Department of Chemistry, University of Aberdeen, Meston Walk, Aberdeen, AB24 3UE, UK
- P50 The effects of zoledronate on iliac bone remodelling in stroke patients  
*KES Poole, N Loveridge, S Vedi, JE Compston, J Reeve\**  
 Division of Bone Research, University of Cambridge, UK
- P51 Serum markers of bone turnover: a novel approach to monitoring the natural history of Charcot Osteoarthropathy  
*C Moniz\*, R Musto, N Petrova, M Edmunds, R Langworthy*  
 Kings College Hospital, Denmark Hill, London SE5 9RS UK
- P52 The use of statins in tissue engineering to enhance human bone cell culture  
*SL Griffiths\*, SH Cartmell*  
 Keele University, Institute of Science and Technology in Medicine, Guy Hilton Research Centre, Stoke, ST4 7QB, UK
- P53 Cultured osteoblasts from osteoarthritic and osteoporotic patients display differential gene expression profiles  
*AJ Allstaff\*, A Hughes, RM Aspden*  
 Bone and Musculoskeletal Programme, University of Aberdeen, Aberdeen, UK
- P54 Bone marrow quantification using 3.0 tesla magnetic resonance imaging  
*CP Bernard<sup>[1]</sup>, GP Liney<sup>\*[1]</sup>, DJ Manton<sup>[1]</sup>, LW Turnbull<sup>[1]</sup>, CM Langton<sup>[2]</sup>*  
<sup>[1]</sup> Centre for MR Investigations, Hull Royal Infirmary, UK; <sup>[2]</sup> Centre for Metabolic Bone Disease, Hull Royal Infirmary, UK
- P55 Habitual physical activity and osteoarthritis: How can we best investigate whether there is a link between them?  
*S Sivakumar\*, A Mavroeidi, DM Reid*  
 University of Aberdeen, Aberdeen, UK
- P56 Sample size requirements for bone density precision assessments and effect on patient misclassification: a Monte Carlo simulation study  
*A Moayyeri<sup>\*[1]</sup>, M Sadatsafavi<sup>[2]</sup>, WD Leslie<sup>[3]</sup>*  
<sup>[1]</sup> Department of Public Health and Primary Care, Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK;<sup>[2]</sup> Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Institute, Vancouver, BC, Canada;<sup>[3]</sup> Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
- P57 Wnt signalling in bone in osteoarthritis and osteoporosis  
*X Hochet, RM Aspden\**  
 Department of Orthopaedics, University of Aberdeen, Scotland, UK
- P58 Key determinants of bone mineral density in exercising young women  
*WWK To<sup>[1]</sup>\*, MWN Wong<sup>[2]</sup>*

- [1] Dept of Obstetrics & Gynaecology, United Christian Hospital, Hong Kong, Hong Kong Special Administrative Region of China;**[2] Dept of Orthopaedics & Traumatology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region of China*
- P59 Metal debris produced during total knee replacement: differences between metal and ceramic cutting jigs  
*S Wimsey\**, *AJ Langdown*  
*Department of Orthopaedic Surgery, Queen Alexandra Hospital, Portsmouth, UK*
- P60 Lack of effect of alendronate therapy on circulating osteoclast precursor cell populations and their osteoclastogenic cytokine receptors  
*SJ Glover\**, *R Eastell*, *A Rogers*  
*University of Sheffield, Sheffield, UK*
- P61 Tumour cell-bone marrow stromal cell interactions modify expression of Cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG)  
*JKL Woodward\**, *DV Lefley*, *NA Cross*, *PD Ottewell*, *DJ Buttle*, *RE Coleman*, *I Holen*  
*University of Sheffield, UK*
- P62 A functional RNAi screening for Runx2-regulated genes corresponding to ectopic bone formation in human spinal ligaments  
*M Kishiya\**<sup>[1,2]</sup>, *H Kudo*<sup>[2]</sup>, *K Kanemaru*<sup>[2]</sup>, *T Numasawa*<sup>[2]</sup>, *T Yokoyama*<sup>[2]</sup>, *S Motomura*<sup>[1]</sup>, *S Toh*<sup>[2]</sup>, *K-I Furukawa*<sup>[1]</sup>  
*[1]Department of Pharmacology, Hirosaki University School of Medicine, Hirosaki, Japan;**[2]Department of Orthopedic Surgery, Hirosaki University School of Medicine, Hirosaki, Japan*
- P63 The pattern of procalcitonin in uncomplicated total hip and knee arthroplasty and its implication in periprosthetic infection  
*SM Ali\**, *A Christ*, *A Chappell*  
*Inverclyde Royal Hospital, Greenock, UK*
- P64 The importance of parathyroid hormone (PTH) assessment in the treatment of autosomal dominant hypophosphataemic rickets  
*N Basu\**, *AJ Black*, *DM Reid*  
*Grampian Osteoporosis Service, Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, Scotland*